<DOC>
	<DOCNO>NCT02196285</DOCNO>
	<brief_summary>Measles rubella highly contagious acute viral disease . As per WHO , several evidence demonstrate benefit providing universal access vaccine contain measles rubella antigen , mainly due , respectively , mortality child malformation fetus . This Phase I , open study , non-controlled , evaluate safety , tolerability imunogenicity double viral vaccine anti-measles rubella ( MR ) , develop produced Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz , Brazil , use human being . 30 eligible volunteer , 18-49 year old , vaccinate monitor local systemic adverse event titration antibody . The study last 20 month total .</brief_summary>
	<brief_title>Study Evaluate Safety Imunogenicity Double Viral Vaccine ( MR ) Measles Rubella</brief_title>
	<detailed_description>This Phase I , open study , non-controlled , evaluate safety , tolerability imunogenicity double viral vaccine anti-measles rubella ( MR ) , develop produced Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz , Brazil , use human being . 30 eligible volunteer , 18-49 year old , vaccinate monitor local systemic adverse event titration antibody . The study last 20 month total .</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male Age 18 49 year old ; Willing provide name , address , telephone contact information order contact , whenever need ( example : case miss schedule visit , contact confirmation schedule visit , urgent safety notification ) ; Willing strictly follow study protocol ; Capacity understand signing Informed Consent Form ; To understand impossibility participate another clinical trial time participation study , 6 month conclusion ; Intellectual level allow fill diary register symptom home ; Willing undergo serological test HIV , HBV HCV ; Being good health , significant medical history ; Physical examination screen period without clinically significant change ; Lab examination screen period within normal range , determine laboratory abnormal value , grade 1 2 , accord medical decision . Serious adverse reaction vaccination , respiratory difficulty , angioedema anaphylaxis ; Acute chronic disease , diabetes , heart disease , systemic arterial hypertension ; Use antiallergic antigen injection maximum timeline 14 day vaccination ; Use immunoglobulin past 12 month study vaccination ; Use blood product within 12 month vaccination ; Use vaccine type within 30 day vaccination study ; Chronic use medication , except homeopathy , trivial one , nasal physiologic solution vitamin ; Previous immunosuppressive cytotoxic medication , last 6 month . Individuals make use kind medication nonimmunosuppressant dos , nasal corticosteroid allergic rhinitis topic corticosteroid noncomplicated dermatitis , 14 day , allow include study . Use kind medication investigation within one year vaccination . Unstable asthma may require urgent care , hospitalization intubation within last 2 year , require use oral intravenous corticosteroid . Coagulopathies diagnose physician report capillary fragility ( ex : bruise bleeding without justifiable cause ; Convulsions , except one cause fever , 2 year old ; Psychiatric disease difficults adherence protocol , psychosis , obsessivecompulsive disorder , bipolar disease treatment , diseases require treatment lithium suicidal idea last 5 year inclusion ; Active malignant ( p.e . kind cancer ) treat disease , individual may relapse study ; Asplenia ( absence spleen removal ) ; Positive HIV screen examination history immunosuppressant disease ; Positive serology C hepatitis screen evaluation ; Positive Antigen HBs screen evaluation ; Alcoholism ( CAGE criterion ) , use detection abusive drinker alcoholic , validated Brazilian population sensibility 88 % specificity 83 % , two answer , among four possible , afirmative ( Mansur Monteiro , 1983 ) , accord medical decision ; Abuse illicit drug , accord medical decision ; Acquired congenital immunodeficiency ; Allergy vaccine compound , egg , neomycin gelatin .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Double</keyword>
	<keyword>Viral</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Measles</keyword>
	<keyword>Rubella</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Imunogenicity</keyword>
</DOC>